BioCentury
ARTICLE | Clinical News

Selecta's gene therapy improves survival in MMA mice

May 19, 2017 7:11 PM UTC

Selecta Biosciences Inc. (NASDAQ:SELB) said its Anc80-synMUT gene therapy corrected methylmalonyl CoA mutase (MUT) mutations and led to survival benefits in mouse models of methylmalonic acidemia (MMA)...